RDNT
RadNet, Inc.
NASDAQ · USHealthcareMedical - Diagnostics & Research
$60.68-2.43%
Price as of Jul 20, 2026
RDNT growth
RadNet, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +14.7%
- EBITDA
- +43.2%
- EBIT
- +18.9%
- EPS
- +59.4%
- Free cash flow
- —
- Operating cash flow
- +35.8%
Forward estimates
- Revenue
- +10.3%
- EBITDA
- +34.0%
- EPS
- +677.9%
Three-year CAGR
- Revenue
- +12.6%
- EBITDA
- -3.0%
- EBIT
- +25.1%
- Net income
- —
- EPS
- —
- Free cash flow
- +39.0%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.